AAP
BIOA

Arax Advisory Partners’s BioAge Labs BIOA Stock Holding History

Arax Advisory Partners’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$53 – 4416
2025
Q4 		$53 Sell
4
-470
-99% -$4.17K ﹤0.01% 3910
2025
Q3 		$2.79K Buy
+474
New +$2.22K ﹤0.01% 3028

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Arax Advisory Partners's BIOA Position: Q1 2026 in Review

Arax Advisory Partners sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 4 shares — an estimated $53 sold.

Arax Advisory Partners first reported a position in BIOA in Q3 2025 and held it in 2 quarters. The position peaked at $2.79K in Q3 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Arax Advisory Partners reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 4 BioAge Labs shares in Q1 2026, an estimated $53.
  • Arax Advisory Partners first reported a position in BioAge Labs in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's BioAge Labs position peaked at $2.79K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.